Compare ARTW & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARTW | HIND |
|---|---|---|
| Founded | 1956 | 2017 |
| Country | United States | United States |
| Employees | N/A | 18 |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4M | 15.2M |
| IPO Year | 1996 | 2016 |
| Metric | ARTW | HIND |
|---|---|---|
| Price | $2.48 | $2.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 8.9K | ★ 13.9K |
| Earning Date | 04-13-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 233.33 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $22,975,408.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $64.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.04 | $1.75 |
| 52 Week High | $4.69 | $12.87 |
| Indicator | ARTW | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 40.65 | 45.12 |
| Support Level | $2.07 | $1.99 |
| Resistance Level | $2.52 | $2.36 |
| Average True Range (ATR) | 0.11 | 0.11 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 16.67 | 8.00 |
Art's-Way Manufacturing Co Inc is a manufacturer of agricultural equipment. It has two reportable segments: Agricultural Products and Modular Buildings. The Agricultural Products segment fabricates and sells farming products as well as related equipment and replacement parts for these products in the United States and world wide. Its Modular Buildings segment manufactures and installs modular buildings for animal containment and various laboratory uses. It derives revenues from the Agricultural Products segment.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.